Hexapeptide-3 (CAS 1205679-02-2) is supplied by TCS NEXUS S.L. (Valencia, Spain) for European cosmetic formulators, brand R&D teams and B2B buyers reviewing cosmetic peptide raw material applications. A freely water-soluble peptide, it dissolves directly in aqueous concentrates without co-solvents at pH 4.5–7.0, with cool-down addition below 45°C recommended in standard serum and leave-on manufacturing protocols.
> Technical Specifications
| Product Name | Hexapeptide-3 |
|---|---|
| Molecular Structure |  |
| CAS Number | 1205679-02-2 |
| Alias / Common Name | Hexapeptide-3; Hexapeptide-8 Amide |
| Molecular Formula | C32H58N14O11S |
| Molecular Weight | 847.0 g/mol |
| INCI Name | Hexapeptide-3 |
| Functional Class | Synthetic hexapeptide; SNAP-25 N-terminal domain biomimetic; SNARE complex modulator; expression-line active |
| Purity / Assay | ≥98% (HPLC); confirm by batch COA |
| Appearance | White to off-white powder |
| Solubility / Handling | Freely water-soluble; dissolve in deionised water or aqueous phase at ambient temperature; no co-solvent required |
| pH Stability | Optimal stability at pH 4.5–7.0; confirm in target formulation base after all actives |
| Storage | Store sealed below 25°C in cool, dry, light-protected conditions; follow batch COA and SDS |
> Mechanism & Positioning
Hexapeptide-3 (Hexapeptide-8 Amide, CAS 1205679-02-2) is a synthetic hexapeptide belonging to the SNAP-25 N-terminal domain biomimetic class, designed to interfere with SNARE complex assembly at the neuromuscular junction through competitive interaction at the SNAP-25 / syntaxin / VAMP complex interface. Published Hexapeptide-3 literature discusses SNARE complex competitive binding — the hexapeptide sequence mimics the SNAP-25 N-terminal domain segment that engages in the four-helix SNARE bundle assembly required for acetylcholine vesicle membrane fusion and neurotransmitter release. Cell-based neuromuscular studies document reduced SNARE complex assembly efficiency and attenuated acetylcholine-mediated muscle contraction signalling in in vitro neuromuscular model systems at evaluated concentrations. SNARE complex model data also notes that the amide C-terminal modification of Hexapeptide-3 (Hexapeptide-8 Amide) provides enhanced peptidase resistance relative to free carboxyl-terminus SNAP-25 biomimetics, with potential implications for in situ peptide stability at the neuromuscular target site.
Based on available in vitro data, Hexapeptide-3 is positioned for expression-line serum, anti-wrinkle concentrate and periorbital formulation concepts where SNARE complex modulation is the primary mechanistic direction. The SNAP-25 biomimetic mechanism places Hexapeptide-3 in the same class as Argireline (Acetyl Hexapeptide-8) and SNAP-8 (Acetyl Octapeptide-3) for comparative formulation evaluation, with all three targeting SNARE complex assembly through SNAP-25 N-terminal domain mimicry.
> Application Concepts
Expression-Line Serum Architecture: SNARE-Class Hexapeptide
Hexapeptide-3 is freely water-soluble at 0.001–0.01% (w/w) in glycerin–water, hyaluronic acid solutions and buffered aqueous serum bases without co-solvent requirement. Introduce during the cool-down phase below 45°C alongside other SNARE-class or complementary neuromuscular actives. For multi-mechanism neuromuscular positioning, Hexapeptide-3 (SNARE complex) may be combined with Pentapeptide-18 (Leuphasyl, GABAergic presynaptic Ca²⁺) and Syn-Ake or Vialox (postsynaptic nAChR) for three-mechanism pre- and postsynaptic expression-line attenuation. All are water-soluble, pH-compatible at 4.5–7.0 and added at cool-down below 45°C. Confirm combined stability via HPLC assay retention at 40°C/75% RH.
Comparison with Argireline and SNAP-8 for SNARE-Class Evaluation
Hexapeptide-3, Argireline (Acetyl Hexapeptide-8) and SNAP-8 (Acetyl Octapeptide-3) all target SNARE complex assembly via SNAP-25 N-terminal domain mimicry. The three molecules differ in: (i) N-terminal acetylation status (Argireline and SNAP-8 are N-acetylated; Hexapeptide-3 is reportedly C-amidated); (ii) sequence length (6aa for Argireline and Hexapeptide-3; 8aa for SNAP-8); and (iii) CAS-defined structural specifics. In development protocols, formulators evaluate these three SNARE-class peptides side-by-side at 0.001–0.01% (w/w) in the same aqueous serum base to compare relative SNARE complex inhibition profiles. All are water-soluble and pH-compatible at 4.5–7.0. Contact info@tcspeptides.com to request evaluation samples for side-by-side comparison.
Periorbital and Forehead Targeted Expression-Line Formulations
The SNARE complex modulation mechanism of Hexapeptide-3 is directly relevant for periorbital (orbicularis oculi) and forehead (frontalis/corrugator) targeted treatments where expression lines from repeated muscle contraction are the formulation target. At 0.001–0.01% (w/w) in lightweight eye-contour gel, cream-gel or forehead serum formats, Hexapeptide-3 integrates without co-solvent and is compatible with standard periorbital actives (caffeine, niacinamide, hyaluronic acid) at pH 5.0–6.5. For comprehensive periorbital neuromuscular coverage, combine with Leuphasyl (Pentapeptide-18) for complementary presynaptic GABAergic Ca²⁺ pathway modulation alongside SNARE complex activity. Confirm combined stability and assay retention before scale-up.
> Handling & Formulation Notes
Dissolve Hexapeptide-3 in deionised water or the aqueous phase at ambient temperature at 0.001–0.01% (w/w) without co-solvent. Freely water-soluble at these concentrations. Introduce during cool-down phase below 45°C. Maintain formulation pH within 4.5–7.0.
Evaluate compatibility with preservative systems at target concentrations. The Met residue in some SNAP-25 biomimetics is susceptible to oxidation — evaluate EDTA compatibility and oxidising agent exposure. Confirm peptide assay retention by HPLC after accelerated stability at 40°C/75% RH before production.
> Supply & Documentation
Hexapeptide-3 (CAS 1205679-02-2) is available from TCS NEXUS S.L. (Valencia, Spain) for B2B cosmetic raw material projects. Standard documentation: COA, TDS, SDS. Sample and bulk quantities are discussed on a per-project basis; contact info@tcspeptides.com to initiate a sourcing review.
TCS NEXUS S.L. supports procurement and formulation teams in Germany, France, Italy, Spain, the United Kingdom, the Netherlands, Belgium, Poland, Sweden and Portugal, as well as international buyers in the United States, Canada, Japan, South Korea, Australia and New Zealand.
> Packaging & Storage
Hexapeptide-3 is supplied in sealed aluminium foil bags or bulk containers. Minimum quantities and packaging configurations are confirmed per order. Store below 25°C in a cool, dry location, away from moisture and direct light. Follow batch COA and SDS for specific storage and handling conditions.
> FAQ
What is Hexapeptide-3?
Hexapeptide-3 (CAS 1205679-02-2) is a cosmetic raw material supplied by TCS NEXUS S.L. (Valencia, Spain) for B2B cosmetic formulators. In cosmetic literature, Hexapeptide-3 is positioned as a SNARE-pathway expression-line peptide evaluated for reducing the appearance of repetitive-motion lines in targeted leave-on anti-ageing serums and eye-contour products. TCS NEXUS S.L. supplies Hexapeptide-3 as a B2B synthetic hexapeptide for formulators developing expression-line-reduction products.
What is the CAS number for Hexapeptide-3?
The CAS number for Hexapeptide-3 is 1205679-02-2. The INCI name for cosmetic regulatory documentation and CPNP notification is Hexapeptide-3; confirm CAS 1205679-02-2 and INCI identity against the batch COA when building product files.
How does Hexapeptide-3 relax expression lines — what is the SNARE mechanism?
Hexapeptide-3 is a SNAP-25 N-terminal biomimetic closely related to the Acetyl Hexapeptide-8 (Argireline) family. Like those peptides it is discussed as competing with native SNAP-25 within the SNARE complex at the neuromuscular junction, attenuating the acetylcholine release that drives the micro-contractions behind expression lines — positioning it for expression-line and anti-wrinkle claim directions.
What use level of Hexapeptide-3 is typical, and how should it be evaluated?
Because the effective level shifts with formulation and claim, build it up conservatively from your own evaluation instead of fixing on one number; it is often a trade solution, so confirm your dosing basis. We supply the pure material with COA — contact info@tcspeptides.com to align documentation.
Which actives pair with Hexapeptide-3 in an expression-line system?
As a SNARE-pathway peptide, Hexapeptide-3 combines with other neuromuscular peptides on complementary routes — Leuphasyl (Pentapeptide-18, GABAergic) and Syn-Ake (nAChR) — and with matrix peptides such as Matrixyl for all-round age-care. It is water-soluble; confirm combined stability and pH in the finished base.
How does Hexapeptide-3 relate to Argireline (Acetyl Hexapeptide-8)?
Hexapeptide-3 belongs to the same SNAP-25 N-terminal mimetic family as Argireline (Acetyl Hexapeptide-8) and acts on the same presynaptic SNARE mechanism; it is offered as a related expression-line option that can be selected or combined based on formulation brief. Hexapeptide-3 is freely water-soluble and dissolves directly in the aqueous phase.
What addition temperature is recommended for Hexapeptide-3 during manufacturing?
Introduce Hexapeptide-3 during the cool-down phase at temperatures below 45°C; avoid prolonged exposure above this threshold. Standard aqueous or emulsion cool-down protocols are fully compatible with this addition requirement. Confirm thermal stability in the specific manufacturing process with accelerated stability data before committing to production scale.
What pH range keeps Hexapeptide-3 stable in a finished formula?
Hexapeptide-3 is most stable at roughly pH 4.5–7.0; confirm the finished-product pH after all actives are incorporated and evaluate combined stability with low-pH actives such as ascorbic acid.
Is Hexapeptide-3 compatible with other actives in multi-active cosmetic systems?
Hexapeptide-3 is compatible with standard cosmetic actives at pH 4.5–7.0 in aqueous or emulsion systems. Evaluate combined system pH drift, clarity and assay retention; confirm preservative compatibility. Run accelerated stability testing at 40°C/75% RH before scale-up.
Is Hexapeptide-3 (INCI) compliant with EU Cosmetics Regulation 1223/2009?
Hexapeptide-3 is not listed as a restricted, prohibited or regulated substance under EU Cosmetics Regulation 1223/2009 Annexes II–VI. The finished product manufacturer is responsible for the CPSR and CPNP notification. Use CAS 1205679-02-2 and INCI name Hexapeptide-3 consistently in all regulatory documentation; confirm purity and identity against the batch COA.
How should Hexapeptide-3 be stored?
Store Hexapeptide-3 sealed below 25°C in a cool, dry location protected from direct light and moisture. Once opened, reseal the container immediately. Follow specific storage and handling conditions stated in the SDS and batch COA. Confirm shelf life for the specific batch before incorporating into production formulations.
What documentation does TCS NEXUS S.L. provide for Hexapeptide-3?
TCS NEXUS S.L. provides COA (confirming CAS 1205679-02-2 and HPLC purity ≥98% (HPLC)), TDS (Technical Data Sheet) and SDS (Safety Data Sheet) for Hexapeptide-3. Additional documentation such as specification sheets and INCI confirmation letters is available on a per-project basis. Contact info@tcspeptides.com to initiate a documentation and sourcing discussion.
What MOQ and sample options are available for Hexapeptide-3?
Sample and bulk quantities for Hexapeptide-3 are confirmed on a per-project basis through TCS NEXUS S.L. Minimum order quantities depend on current stock, packaging configuration and project scope. R&D teams are encouraged to request samples for stability and concentration-range evaluation before bulk planning. Contact info@tcspeptides.com with project specification to begin a sourcing review.
> Technical Support and Samples
Request COA documents, sample availability, or support for custom synthesis.